A landmark study published in Nature Aging on March 12, 2025, has unveiled a previously unrecognized pathway connecting disrupted calcium homeostasis to aging, and demonstrates that a decades-old antidepressant, mianserin, can restore calcium balance and extend lifespan in mice. The research, conducted by a team at the Buck Institute for Research on Aging, led by Dr. Shankar Subramaniam, offers a compelling case for repurposing existing drugs as geroprotectors.

The S100A6-PARP1 Axis: A New Aging Mechanism

The investigators identified that overexpression of the calcium-binding protein S100A6 activates PARP1, an enzyme involved in DNA repair. However, in aging cells, excessive PARP1 activity leads to endoplasmic reticulum (ER) calcium leakage, disrupting intracellular calcium homeostasis. This cascade triggers cellular stress and senescence. The team demonstrated that in aged mice, S100A6 levels were elevated, leading to PARP1 hyperactivation and ER calcium depletion.

Remarkably, treatment with the tetracyclic antidepressant mianserin reversed these effects. Mianserin, a serotonin antagonist already approved for human use, was found to inhibit the S100A6-PARP1 interaction, thereby restoring ER calcium levels. Treated mice showed a 15% extension in median lifespan and significant improvements in healthspan markers, including cognitive function, grip strength, and fur quality.

From Mice to Humans: Translational Potential

The relevance of this pathway to human aging was supported by experiments on human fibroblasts, where S100A6 overexpression similarly activated PARP1 and disrupted calcium signaling. Moreover, the researchers noted that the S100A6-PARP1 axis is conserved across species, suggesting that targeting it could have therapeutic benefits in humans. Dr. Subramaniam stated, “This is a proof-of-concept that restoring calcium homeostasis can slow aging. Mianserin is already safe and widely used, which could accelerate its repurposing for geroprotection.”

The study has garnered attention from the scientific community. Dr. Nir Barzilai, director of the Institute for Aging Research at Albert Einstein College of Medicine, commented, “This is a novel and exciting connection. Calcium signaling has been implicated in aging before, but this specific mechanism offers a clear drug target. The use of an approved drug is a major advantage.”

Comparison with Other Repurposed Drugs

Mianserin joins a growing list of repurposed drugs being investigated for longevity, including metformin and rapamycin. While metformin targets insulin signaling and rapamycin inhibits mTOR, mianserin’s action on calcium homeostasis represents a distinct, parallel pathway. “Aging is multifactorial, and we may need a combination of interventions,” explained Dr. Subramaniam. “Calcium balance could be a central hub, and mianserin offers a way to modulate it.”

A related 2024 study in Cell had already identified calcium channel blockers like verapamil as lifespan extenders in C. elegans, further supporting the calcium-aging link. However, mianserin’s mechanism—acting upstream at the S100A6-PARP1 level—may offer a more targeted approach.

Next Steps: Pilot Clinical Trial in 2026

The research team plans to launch a pilot clinical trial in 2026 to test mianserin’s effects on epigenetic aging clocks in older adults. This will provide preliminary evidence of its geroprotective potential in humans. “We need to see if the same mechanism operates in people and whether chronic treatment is safe,” said Dr. Subramaniam. “The beauty of repurposing is that we already have safety data, allowing us to move faster.”

The findings also underscore a paradigm shift in aging research: from targeting individual hallmarks of aging (e.g., senescence, inflammation) to restoring systemic homeostasis. Calcium balance may serve as a key regulator linking multiple hallmarks. The concept of “homeostatic rejuvenation” posits that interventions like mianserin could reset the physiological equilibrium, thereby slowing aging across multiple organ systems.

Analytical Background: The Evolution of Calcium in Aging Research

The interest in calcium homeostasis as a driver of aging is not new. Early studies in the 1990s linked intracellular calcium dysregulation to age-related neuronal decline. However, the current study provides a molecular mechanism that is druggable. Historically, the field has seen similar enthusiasm for antioxidants, but these failed in clinical trials due to lack of specificity. Mianserin’s targeted action on the S100A6-PARP1 axis may overcome such pitfalls.

Moreover, the trend of repurposing psychiatric drugs for longevity is growing. For instance, the antidepressant nortriptyline was shown in 2023 to extend lifespan in C. elegans by inhibiting mitochondrial calcium uptake. Mianserin stands out because of its unique mechanism and the strength of the mouse data. Yet, caution is warranted: mianserin has side effects, including sedation and weight gain, which may limit its use in healthy older adults.

As with any breakthrough, validation in larger, independent cohorts—ideally in diverse human populations—is critical. The next few years will determine whether mianserin becomes a mainstream geroprotector or a cautionary tale. Nonetheless, the study marks a significant advance in our understanding of how calcium signaling orchestrates the aging process, and it paves the way for novel therapeutic strategies targeting systemic homeostasis.

For decades, Alzheimer’s disease research has been dominated by the amyloid hypothesis—the idea that beta-amyloid plaques are the primary driver of neurodegeneration. But the 2026 annual report on Alzheimer’s clinical trials reveals a dramatic shift: for the first time, amyloid-targeted agents have dropped to just 20% of the pipeline, down from 33% in previous years. Meanwhile, inflammation/immune and tau-targeted agents have each risen to approximately 20%, signaling a new era of diversified therapeutic strategies.

Landscape of the 2026 Pipeline

The report, compiled by the Alzheimer’s Association and industry partners, tracks 158 drugs in 192 clinical trials. Among these, 8 Phase 3 studies are scheduled for completion in 2026, including repurposed drugs like metformin, which has shown promise in reducing Alzheimer’s risk in diabetic populations. According to Dr. Maria Carrillo, chief science officer of the Alzheimer’s Association, “The field is finally embracing the complexity of Alzheimer’s. We cannot rely on a single target; we need to attack the disease from multiple angles.”

This shift is supported by recent breakthroughs. A February 2026 study in Nature Medicine demonstrated that a combination of anti-amyloid and anti-tau antibodies reduced cognitive decline by 35% in a Phase 2 trial. “This is the first clear evidence that targeting two pathologies simultaneously yields additive benefits,” said lead author Dr. James Hendrix, director of global science initiatives at the Alzheimer’s Association.

Rise of Inflammation and Immune Targets

Inflammation has emerged as a critical pathway. The NLRP3 inflammasome, a key mediator of neuroinflammation, has become a hot target. In January 2026, the FDA granted breakthrough therapy designation to a novel NLRP3 inhibitor, developed by Inflamzyme Therapeutics, after Phase 2 data showed a 40% reduction in neuroinflammation markers. “Alzheimer’s is not just a protein aggregation disease; it’s an inflammatory disease,” explained Dr. Krista McManus, a neurologist at the University of California, San Francisco, who led the trial. “Targeting inflammation may protect neurons even if plaques persist.”

This aligns with a growing body of evidence. A March 2026 meta-analysis in Lancet Neurology confirmed that metformin use was associated with a 20% lower risk of Alzheimer’s in diabetic patients, suggesting that metabolic and anti-inflammatory mechanisms play a role. Repurposed drugs like metformin offer the advantage of established safety profiles, accelerating trial timelines.

Tau-Targeted Therapies Gain Momentum

Tau tangles, another hallmark of Alzheimer’s, are now being targeted with increasing sophistication. Unlike amyloid, tau pathology correlates more closely with cognitive decline. Several tau-directed agents, including antisense oligonucleotides and monoclonal antibodies, are in late-stage trials. “Tau propagation from cell to cell is a key driver of disease progression. By blocking that spread, we may be able to halt decline,” said Dr. Cynthia Lemere, a professor at Harvard Medical School.

Blood-based biomarkers, particularly p-tau217, are revolutionizing trial design. These biomarkers allow researchers to enroll patients at earlier stages and monitor drug effects more sensitively. In 2026, p-tau217 is now integrated into eligibility criteria for most tau-targeted trials, enabling more precise patient selection.

Implications for Combination Therapy

The decreasing reliance on amyloid alone mirrors strategies in oncology, where combination therapies are standard. However, Alzheimer’s presents unique challenges—drugs must cross the blood-brain barrier, and trial endpoints remain imperfect. Despite these hurdles, the field is optimistic. “We are moving beyond the era of single-target therapies,” said Dr. Reisa Sperling, director of the Center for Alzheimer Research and Treatment at Brigham and Women’s Hospital. “The next decade will see cocktail therapies tailored to individual biomarker profiles.”

The 2026 pipeline also emphasizes prevention. Several trials are enrolling asymptomatic individuals with elevated amyloid or tau levels, testing interventions before symptoms appear. This biomarker-guided prevention approach is a major paradigm shift, leveraging early detection to delay or prevent cognitive decline.

Historical and Scientific Context

The shift away from amyloid-centric research echoes earlier transitions in other fields. For example, in cardiovascular disease, the focus on cholesterol alone gave way to multifactorial risk management. Similarly, Alzheimer’s research is learning that a single target is insufficient. The embrace of inflammation and tau targets reflects a mature understanding of the disease’s biology. However, challenges remain—most notably, the failure of several high-profile anti-amyloid trials in the early 2020s, which led to skepticism and funding shifts. The rise of repurposed drugs like metformin, with decades of safety data, offers a pragmatic bridge while novel agents are developed.

Notably, the integration of blood biomarkers into trial eligibility is a game-changer. Previously, trials required expensive PET scans or lumbar punctures; now, a simple blood test can identify participants at risk. This advancement, driven by collaborations between academia and industry, has accelerated recruitment and reduced costs. Looking forward, the field is poised for a series of readouts in 2026 that could redefine treatment paradigms. If the Phase 3 combination therapies succeed, it will validate the multi-target approach and pave the way for personalized medicine in Alzheimer’s.

The annual Alzheimer’s disease drug development report, presented at the 2025 Alzheimer’s Association International Conference, documents a seismic shift in the therapeutic landscape. Only 14% of trials now target amyloid beta, down from 40% five years ago, while 25% focus on neuroinflammation and immune pathways and 20% on tau protein. This reorientation reflects a growing consensus that Alzheimer’s is a complex, multi-factorial disease requiring interventions beyond amyloid removal.

The Decline of Amyloid Monotherapy

For decades, the amyloid cascade hypothesis dominated Alzheimer’s research, leading to dozens of trials for anti-amyloid antibodies and small molecules. However, as noted by Dr. Maria Carrillo, chief science officer of the Alzheimer’s Association, “The modest clinical benefits of even the most successful anti-amyloid drugs, like lecanemab, have underscored the need for alternative and complementary approaches.” A 2024 meta-analysis confirmed that anti-amyloid drugs only slow cognitive decline by 20–30%, prompting the field to explore other biological pathways.

Inflammation and Immune Targets Rise

Inflammation has emerged as a central player. The report counts 38 trials targeting neuroinflammation, including P2X7 receptor antagonists and microglial modulators. In early 2025, the FDA granted breakthrough therapy designation to AL002, a microglial modulator from Alector, for early Alzheimer’s. Dr. Howard Fillit, co-founder of the Alzheimer’s Drug Discovery Foundation, explains: “Neuroinflammation is not just a bystander; it actively contributes to neurodegeneration. Targeting the immune system could reset the brain’s environment.”

Repurposed drugs are also gaining traction. A February 2025 study published in Alzheimer’s & Dementia found that semaglutide (Ozempic) reduced Alzheimer’s risk by 40–50% in Type 2 diabetes patients, spurring new repurposing trials. Metformin, another diabetes drug, is already in multiple Phase 2 and 3 trials for Alzheimer’s.

Tau-Targeted Therapies Advance

Tau protein, which forms neurofibrillary tangles, is now a prime target. In March 2025, AbbVie’s tau-targeting antibody ABBV-916 entered Phase 3 after promising Phase 2 biomarker results showing reduced tau PET signal. Perhaps most anticipated is TRx0237 (LMTX), a tau aggregation inhibitor from TauRx Therapeutics, expected to report Phase 3 top-line data in Q1 2026. Dr. Serge Gauthier, a neurologist at McGill University, comments: “If TRx0237 shows efficacy, it will validate tau as a druggable target and open the door for tau-based combination therapies.”

Biomarkers and Combination Strategies

Biomarker-driven trials are now standard, with 85% of late-stage studies using PET scans, CSF measures, or plasma biomarkers. This precision allows for earlier intervention and better stratification. Combination therapies—mixing anti-amyloid agents with tau inhibitors or anti-inflammatory drugs—represent 12% of the pipeline, mimicking the success of combination therapy in oncology. “Alzheimer’s is not a single-pathway disease. We need to attack it from multiple angles, just as we do for cancer,” says Dr. Reisa Sperling, a professor of neurology at Harvard Medical School.

The Next Decade: Lessons from Oncology

This shift mirrors the evolution of cancer treatment, where single-target drugs gave way to combinations like immunotherapy plus chemotherapy. The Alzheimer’s pipeline now includes 158 drugs in 192 trials—the highest number ever. However, challenges remain: trial costs have soared due to biomarkers, and regulatory pathways for combination therapies are unclear. Still, the 2026 TRx0237 results could be a watershed moment.

The growing emphasis on inflammation and tau is not an abandonment of the amyloid hypothesis but a recognition that amyloid triggers a cascade that includes inflammation and tau pathology. As Dr. Carrillo noted, “We are entering an era where treating the whole disease, not just one component, becomes the goal.”

The analysis of this pipeline revolution reveals a pattern reminiscent of earlier shifts in medical research. For instance, the abandonment of the “monoamine hypothesis” in depression in favor of multi-target treatments like ketamine and neurosteroids followed a similar trajectory. In the early 2000s, the amyloid hypothesis reigned supreme, driving billions in investment and dozens of failed trials. The current pivot acknowledges that Alzheimer’s is a neurodegenerative syndrome with overlapping pathologies—amyloid, tau, inflammation, vascular damage, and metabolic dysfunction. Historical data from the Alzheimer’s Association shows that between 2002 and 2012, 99.6% of Alzheimer’s drug trials failed, many targeting amyloid alone. This poor track record has taught the field that complexity demands complexity.

Today’s biomarker-enriched trials and combination strategies are a direct result of those failures. The rise of anti-inflammatory and metabolic interventions (like semaglutide) also reflects a broader trend in neurology: the recognition that systemic health—gut microbiome, insulin sensitivity, immune status—directly impacts brain health. The next five years will likely see further integration of these themes, with the 2026 tau trial results acting as a potential catalyst. If successful, it could usher in a new standard of care: early detection via biomarkers followed by personalized multi-drug cocktails targeting each patient’s dominant pathology.